Search Result

Results for "

BRAF inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) APC (1) Apoptosis (29) Aurora Kinase (1) Autophagy (17) Bcl-2 Family (4) Bcr-Abl (4) c-Fms (1) c-Kit (2) c-Met/HGFR (2) c-Myc (1) Caspase (4) CDK (4) COX (1) Discoidin Domain Receptor (2) EGFR (12) Ephrin Receptor (3) ERK (13) Eukaryotic Initiation Factor (eIF) (1) FAK (1) Ferroptosis (6) FGFR (3) FLT3 (7) HSP (1) Isotope-Labeled Compounds (5) JNK (1) Ligands for E3 Ligase (1) LIM Kinase (LIMK) (1) Lipoxygenase (1) MAP3K (1) MEK (11) Molecular Glues (1) NF-κB (1) Oxidative Phosphorylation (2) p38 MAPK (10) Parasite (2) PDGFR (2) PERK (6) PKC (1) PROTACs (3) Raf (129) Ras (5) Reference Standards (12) RET (6) Ribosomal S6 Kinase (RSK) (2) Src (5) Tie (1) VEGFR (17) Xanthine Oxidase (1) YAP (2)
By Research Areas:	Cancer (150) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (1)

By Targets:

Akt (3)

APC (1)

Apoptosis (29)

Aurora Kinase (1)

Autophagy (17)

Bcl-2 Family (4)

Bcr-Abl (4)

c-Fms (1)

c-Kit (2)

c-Met/HGFR (2)

c-Myc (1)

Caspase (4)

CDK (4)

COX (1)

Discoidin Domain Receptor (2)

EGFR (12)

Ephrin Receptor (3)

ERK (13)

Eukaryotic Initiation Factor (eIF) (1)

FAK (1)

Ferroptosis (6)

FGFR (3)

FLT3 (7)

HSP (1)

Isotope-Labeled Compounds (5)

JNK (1)

Ligands for E3 Ligase (1)

LIM Kinase (LIMK) (1)

Lipoxygenase (1)

MAP3K (1)

MEK (11)

Molecular Glues (1)

NF-κB (1)

Oxidative Phosphorylation (2)

p38 MAPK (10)

Parasite (2)

PDGFR (2)

PERK (6)

PKC (1)

PROTACs (3)

Raf (129)

Ras (5)

Reference Standards (12)

RET (6)

Ribosomal S6 Kinase (RSK) (2)

Src (5)

Tie (1)

VEGFR (17)

Xanthine Oxidase (1)

YAP (2)

By Research Areas:

Cancer (150)

Cardiovascular Disease (3)

Infection (2)

Inflammation/Immunology (5)

Metabolic Disease (1)

Neurological Disease (1)

154

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Targets Recommended: Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14660

Dabrafenib 75+ Cited Publications GSK2118436A; GSK2118436	Raf	Cancer
Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC₅₀s of 5 nM and 0.6 nM for C-Raf and B-Raf ^V600E, respectively .

HY-50846

SCH772984 Maximum Cited Publications 182 Publications Verification	ERK	Cancer
SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC₅₀s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-na?ve and MAPK inhibitor-resistant cells containing *BRAF* or RAS mutations .

HY-15605

Encorafenib 40+ Cited Publications LGX818	Raf	Cancer
Encorafenib (LGX818) is a highly potent *BRAF* inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF ^V600E (EC₅₀=4 nM).

HY-12057

Vemurafenib 100+ Cited Publications PLX4032; RG7204; RO5185426	Raf Autophagy	Cancer
Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of *B-RAF* kinase, with IC₅₀s of 31 and 48 nM for RAF ^V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

HY-10966

SB-590885 5+ Cited Publications	Raf Apoptosis	Neurological Disease Metabolic Disease Cancer
SB-590885 is a *BRAF/c-Raf* kinase inhibitor that selectively targets *B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits* the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .

HY-18652

Avutometinib 4 Publications Verification Ro 5126766; CH5126766	MEK Raf	Cancer
Avutometinib (Ro 5126766) is a first-in-class dual MEK/RAF inhibitor that allosterically inhibits BRAF ^V600E, CRAF, MEK, and *BRAF* (IC₅₀: 8.2, 56, 160 nM, and 190 nM, respectively).

HY-12558

LY3009120 10+ Cited Publications DP-4978	Raf Autophagy	Cancer
LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAF ^V600E, BRAF ^WT and CRAF ^WT with IC₅₀s of 5.8, 9.1 and 15 nM, respectively.

HY-112089

Naporafenib 5 Publications Verification LXH254	Raf p38 MAPK Bcr-Abl	Cancer
Naporafenib (LXH254) is a potent, selective, orally active, type II *BRAF* and CRAF inhibitor, with IC₅₀ values of 0.072 and 0.21 nM against CRAF and BRAF, respectively .

HY-158115

NST-628	Molecular Glues Raf MEK	Cancer
NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors .

HY-51424

PLX-4720 15+ Cited Publications	Raf	Cancer
PLX-4720 is a potent and selective inhibitor of B-Raf ^V600E with IC₅₀ of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-Raf ^V600E than wild-type B-Raf.

HY-109080

Belvarafenib 5 Publications Verification HM95573; GDC-5573; RG6185	Raf	Cancer
Belvarafenib (HM95573) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC₅₀s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAF ^v600E and C-RAF respectively .

HY-50864

GDC-0879 4 Publications Verification	Raf	Cancer
GDC-0879 is a potent and selective *B-Raf* inhibitor with an IC₅₀ of 0.13 nM.

HY-15200

Agerafenib 5+ Cited Publications CEP-32496; RXDX-105	Raf	Cancer
Agerafenib (CEP-32496; RXDX-105) is a highly potent and orally efficacious inhibitor of BRAF ^V600E with a K_d of 14 nM.

HY-145120

Mosperafenib RG6344; RO7276389; B-Raf IN 2	Raf	Cancer
*BRAF* inhibitor. RG6344 can be used for the study of BRAF V600-mutant solid tumors, such as colorectal cancer (CRC) .

HY-18972

Plixorafenib 15+ Cited Publications PLX8394; FORE8394	Raf	Cancer
PLX8394 is a potent and selective *BRaf* inhibitor, with an IC₅₀ of appr 5 nM for BRAF ^V600E.

HY-18957

Lifirafenib 2 Publications Verification BGB-283	EGFR Raf	Cancer
Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC₅₀ values of 23 and 29 nM for recombinant BRaf ^V600E and EGFR, respectively.

HY-15767

TAK-632 4 Publications Verification	Raf Aurora Kinase	Cancer
TAK-632 is a potent pan-RAF inhibitor with IC₅₀ of 1.4, 2.4 and 8.3 nM for CRAF, BRAF ^V600E, BRAF ^WT, respectively.

HY-111940

LUT014	Raf p38 MAPK ERK	Inflammation/Immunology
LUT014 is a topical inhibitor targeting *BRAF* that cannot pass through the blood-brain barrier. LUT014 inhibits BRAF kinase and abnormally activates the MAPK/ERK signaling pathway, promoting the proliferation of epidermal keratinocytes, repairing skin barrier damage caused by radiation damage, and alleviating inflammatory responses. LUT014 is independent of RAS signaling and accelerates the repair and regeneration of damaged skin cells. LUT014 can be used to study radiation dermatitis, especially skin damage caused by breast cancer radiotherapy .

HY-11004

AZ 628 10+ Cited Publications	Raf Apoptosis	Cancer
AZ 628 is a pan-Raf kinase inhibitor with IC₅₀s of 105, 34 and 29 nM for *B-Raf, B-RafV600E, and c-Raf-1*, respectively.

HY-18997

PLX7904 3 Publications Verification PB04	Raf	Cancer
PLX7904 is a potent and selective *BRAF* inhibitor, with IC₅₀ of appr 5 nM against BRAF ^V600E in mutant RAS expressing cells.

HY-14177

Raf inhibitor 1 3 Publications Verification	Raf	Cancer
Raf inhibitor 1 is a potent Raf kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-107779

BI-882370	Raf	Cancer
BI-882370 is a potent and selective RAF kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAF ^V600E-mutant, the WT BRAF and CRAF kinases with IC₅₀s of 0.4, 0.8, and 0.6 nM, respectively. BI-882370 also inhibits SRC family kinases .

HY-100510

RAF709 5+ Cited Publications	Raf	Cancer
RAF709 is a potent, selective, and efficacious RAF inhibitor with IC₅₀s of 0.4 nM and 0.5 nM for *BRAF* and CRAF, respectively . Antitumor efficacy .

HY-10247

**BRAF inhibitor** 1 Publications Verification	Raf	Cancer
BRAF inhibitor (Compound P-0850) is a *B-Raf* inhibitor with anti-tumor activity .

HY-159795

Claturafenib PF-07799933; ARRY-440	Raf PERK	Cancer
Claturafenib ( PF-07799933) is an orally active inhibitor of pan-mutant *BRAF. Claturafenib inhibits* pERK in cells (IC₅₀ value of 1.6 nM in HT29 cells). Claturafenib has anticancer activity against BRAF ^G469A mutant NSCLC and BRAF ^K601E mutant melanoma .

HY-12846

CCT196969	Raf	Cancer
CCT196969 is a pan-Raf inhibitor, which inhibits *B-Raf, BRaf* ^V600E and CRAF with IC₅₀s of 0.1, 0.04, and 0.01 μM, respectively.

HY-147405

Tinlorafenib PF-07284890; ARRY-461	Raf ERK	Cancer
Tinlorafenib (PF-07284890) is the orally active inhibitor for *BRAF* and CRAF with IC₅₀s of 5.8 nM and 4.1 nM. Tinlorafenib (Compound 10) inhibits V600E mutated BRAF and V600K mutanted BRAF with IC₅₀s of 4.25 nM and 2.7 nM. Tinlorafenib can cross the blood brain barrier. Tinlorafenib demonstrates CNS penetration and can be used in the research of *BRAF*-associated malignant and benign tumors of the CNS as well as extracranial malignancies .

HY-137487

PROTAC BRAF-V600E degrader-1	PROTACs Raf	Cancer
PROTAC BRAF-V600E degrader-1 (compound 23) is a potent PROTAC BRAF-V600E degrader whlie no degradation activity against BRAF-WT. PROTAC BRAF-V600E degrader-1 exhibits K_d values of 2.4 nM and 2 nM for BRAF and BRAF-V600E, respectively. PROTAC BRAF-V600E degrader-1 degrades BRAF-V600E via the ubiquitin-proteasome system (UPS) and inhibits the growth of melanoma cells . (In the molecular structure, target protein ligand: BI-882370 (HY-107779), red part; E3 ubiquitin enzyme ligand: Pomalidomide (HY-10984), blue part; PROTAC linker: G007-LK (HY-12438), black part.

HY-12787

L-779450 1 Publications Verification	Raf Autophagy	Cancer
L-779450 is a potent and selective *B-Raf* kinase inhibitor with a K_d of 2.4 nM.

HY-12291

HG6-64-1 HMSL 10017-101-1	Raf Apoptosis	Cancer
HG6-64-1 (HMSL 10017-101-1) is a *B-raf* kinase modulator.HG6-64-1 modulates *B-raf* kinase activity, including the V600E mutant form and the drug-resistant gatekeeper mutation T529I. HG6-64-1 is a germinal center kinase inhibitor. HG6-64-1 induces cell cycle arrest and apoptosis. HG6-64-1 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .

HY-15605S

Encorafenib-13C,d3 LGX818-¹³C,d₃	Isotope-Labeled Compounds Raf	Cancer
Encorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Encorafenib. Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM).

HY-117273

AZ304	Raf Autophagy	Cancer
AZ304 is an ATP-competitive dual *BRAF* kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC₅₀s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC₅₀, 6 nM), CSF1R (IC₅₀, 35 nM). Anti-tumor activity .

HY-12847

CCT241161	Raf Src Apoptosis	Cancer
CCT241161 is an orally active pan-RAF inhibitor with IC₅₀s of 3, 6, 10, 15 and 30 nM for LCK, CRAF, SRC, *V600E-BRAF* and *BRAF, respectively. CCT241161 shows good activity to in BRAF* and NRAS mutant melanomas. CCT241161 also exhibits anticancer cell proliferative activity .

HY-P10438

TAT-Braftide	Raf	Cancer
TAT-Braftide is a peptide inhibitor designed to block the dimerization of *BRAF, thereby inhibiting* its kinase activity. The destruction of *BRAF* dimer by TAT-Braftide makes *BRAF* protein more susceptible to proteasome degradation, directly inhibits the activity of *BRAF* kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of RAF kinase in MAPK signaling pathway and for the study of *BRAF* mutant cancers .

HY-77113

B-Raf IN 11	Raf	Cancer
B-Raf IN 11 is a *B-Raf* ^V600E mutant kinase inhibitor with an IC₅₀ of 76 nM, and exhibits an IC₅₀ of 238 nM against wild-type *B-Raf* kinase. B-Raf IN 11 inhibits the kinase activities of *B-Raf* ^V600E mutant and wild-type *B-Raf* kinase. B-Raf IN 11 is applicable to relevant research on colorectal cancer .

HY-18227

B-Raf IN 1	Raf	Cancer
B-Raf IN 1 is a potent and selective *B-Raf* kinase inhibitor with an IC₅₀ of 24 nM.

HY-148059

Uplarafenib B-Raf IN 10	Raf	Cancer
Uplarafenib (B-Raf IN 10) (Compound C09) is a *BRAF* inhibitor with an IC₅₀ between 50 and 100 nM. Uplarafenib shows antitumor activity .

HY-18507

AD57	RET Raf Ribosomal S6 Kinase (RSK) Src	Cancer
AD57 is an orally active multikinase inhibitor, inhibits RET, *BRAF, S6K* and Src, with greatly reduces mTOR activity .

HY-149380

Vem-L-Cy5	Raf	Cancer
Vem-L-Cy5 (compound 3)，modified with the NIR fluorophore cyanine-5 (Cy5)，is a Vemurafenib (HY-12057)-based inhibitor of *BRAF. Vem-L-Cy5 targets to BRAF* ^V600E，and also inhibits MEK phosphorylation. Vem-L-Cy5 has cell permeability，and inhibits cell growth of many types of cancer .

HY-136567

TBAP-001	Raf	Cancer
TBAP-001 (Synthesis 13), extracted from patent WO2015075483A1, is a pan-RAF kinase inhibitor, with an IC₅₀ of 62 nM in BRAF V600E kinase assay .

HY-175831

BRAFV600E-IN-2	Raf	Cancer
BRAFV600E-IN-2 is a BRAF V600E inhibitor with IC₅₀ ≤10 nM. BRAFV600E-IN-2 has anti-tumor activity .

HY-P10436

Braftide	Raf	Cancer
Braftide is an allosteric inhibitor for BRAF kinase by targeting the dimer interface of BRAF kinase and inhibiting the formation of BRAF dimers. Braftide inhibits wild-type BRAF and oncogenic BRAF ^G469A with IC₅₀ of 364 nM and 172 nM, respectively. Braftide inhibits MAPK signaling pathway, inhibits proliferation of KRAS mutant tumor cells (EC₅₀ is 7.1 and 6.6 μM, for HCT116 and HCT-15), in combination of TAT sequence. Braftide can be used for cancer research .

HY-155736

MAPK-IN-2	p38 MAPK EGFR Raf CDK c-Met/HGFR	Cancer
MAPK-IN-2 (compound 3h) is a potent MAPK inhibitor with antineoplastic activity. MAPK-IN-2 inhibits cancer cell proliferation among serval cancer cell lines, and suppresses MAPK pathway with potant efficacy (EGFR ^WT IC₅₀=281 nM, c-MET IC₅₀=205 nM, B-RAF ^WT IC₅₀=112 nM, and CDK4/6 IC₅₀=95 and 184 nM, respectively). MAPK-IN-2 even shows a remarkable potency against mutated EGFR and B-RAF (EGFR ^T790M IC₅₀=69 nM and B-RAF ^V600E IC₅₀=83 nM) .

HY-144269

SHR902275	Raf	Cancer
SHR902275 is a potent, selective, and orally active RAF inhibitor targeting RAS mutant cancers. SHR902275 has IC₅₀s of 1.6 nM, 10 nM, and 5.7 nM for cRAF, bRAF ^wt, and bRAF ^V600E, respectively. SHR902275 shows cell growth inhibition with GI₅₀s of 1.5 and 0.17 nM, 0.4 nM and 0.32 nM for H358, A375, Calu6, and SK-MEL2 cells respectively .

HY-10201S1

Sorafenib-d4 Bay 43-9006-d₄	Raf VEGFR FLT3 Ferroptosis Autophagy Apoptosis	Cancer
Sorafenib-d₄ (Bay 43-9006-d₄) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

HY-15199

Agerafenib hydrochloride CEP-32496 hydrochloride; RXDX-105 hydrochloride	Raf	Cancer
Agerafenib hydrochloride is a highly potent and orally efficacious inhibitor of BRAF ^V600E with a K_d of 14 nM.

HY-126298

RAF mutant-IN-1	Raf	Cancer
RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC₅₀ values of 21 nM, 30 nM and 392 nM for C-RAF ^340D/Y341D, B-RAF ^V600E and B-RAF ^WT, respectively .

HY-15198

KG5	Raf PDGFR FLT3 c-Kit	Cancer
KG5 is an orally active dual PDGFRβ and *B-Raf* allosteric inhibitor. KG5 also inhibits Flt3, KIT and c-Raf. KG5 has anticancer, antiangiogenic activities .

HY-14177A

Raf inhibitor 1 dihydrochloride 3 Publications Verification	Raf	Cancer
B-Raf inhibitor 1 dihydrochloride is a potent Raf kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-137488

PROTAC BRAF-V600E degrader-2	PROTACs Raf	Cancer
PROTAC BRAF-V600E degrader-2 (compound 12) is a potent *BRAF-V600E* degrader with K_ds of 14.4 nM and 9.5 nM for BRAF and BRAF-V600E, respectively. PROTAC BRAF-V600E degrader-2 selectively degraded the kinase domain of BRAF-V600E but not the wild-type BRAF. PROTAC BRAF-V600E degrader-2 inhibits melanoma cell growth .

Cat. No.	Product Name	Type

HY-114491

Rineterkib

Fluorescent Dyes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

HY-10966G

SB-590885

Fluorescent Dyes

SB-590885 GMP is SB-590885 (HY-10966) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .

Cat. No.	Product Name	Type

HY-10966G

SB-590885

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P10438

TAT-Braftide	Raf	Cancer
TAT-Braftide is a peptide inhibitor designed to block the dimerization of *BRAF, thereby inhibiting* its kinase activity. The destruction of *BRAF* dimer by TAT-Braftide makes *BRAF* protein more susceptible to proteasome degradation, directly inhibits the activity of *BRAF* kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of RAF kinase in MAPK signaling pathway and for the study of *BRAF* mutant cancers .

HY-P10436

Braftide	Raf	Cancer
Braftide is an allosteric inhibitor for BRAF kinase by targeting the dimer interface of BRAF kinase and inhibiting the formation of BRAF dimers. Braftide inhibits wild-type BRAF and oncogenic BRAF ^G469A with IC₅₀ of 364 nM and 172 nM, respectively. Braftide inhibits MAPK signaling pathway, inhibits proliferation of KRAS mutant tumor cells (EC₅₀ is 7.1 and 6.6 μM, for HCT116 and HCT-15), in combination of TAT sequence. Braftide can be used for cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N9330

Broussoflavonol F	Flavonols Structural Classification Flavonoids other families Classification of Application Fields Other Diseases Phenols Polyphenols Plants Disease Research Fields Source Classification	Xanthine Oxidase Ras EGFR MEK PERK Apoptosis
Broussoflavonol F is a potent dual inhibitor of the HER2-RAS-MEK-ERK signaling pathway and mushroom tyrosinase with an IC₅₀ value of 82.3 μM. Broussoflavonol F downregulates the expression of RAS, HER2, phosphorylated *BRAF, phosphorylated MEK* and phosphorylated Erk proteins. Broussoflavonol F induces cell cycle arrest and apoptosis, and exhibits cytotoxicity in colon cancer cells. Broussoflavonol F inhibits endothelial proliferation, migration and tube formation, suppresses subintestinal vascular development, and reduces the mRNA levels of angiogenesis-associated genes.Broussoflavonol F can be used for colon cancer research .

Cat. No.	Product Name	Chemical Structure

HY-10201S

Sorafenib-d3 1 Publications Verification
Sorafenib-d₃ (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC₅₀s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively .

HY-15605S

Encorafenib-13C,d3
Encorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Encorafenib. Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM).

HY-10201S2

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-10201S1

Sorafenib-d4
Sorafenib-d₄ (Bay 43-9006-d₄) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

HY-51424S

PLX-4720-d7
PLX-4720-d₇ is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of?B-RafV600E?with?an IC₅₀?of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf .

HY-12057S1

Vemurafenib-d7
Vemurafenib-d₇ is deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC₅₀s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

HY-12057S

Vemurafenib-d5
Vemurafenib-d₅ is the deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC₅₀s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .

HY-10201S4

Sorafenib-d3 tosylate

Sorafenib-d₃ (Donafenib-d₃) tosylate is the deuterium labeled Sorafenib (HY-10201). Sorafenib is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib-d3tosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib-d3tosylate induces autophagy and apoptosis. Sorafenib-d3tosylate has anti-tumor activity. Sorafenib is a ferroptosis activator .

Targets Recommended: Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10966G

SB-590885	Raf Apoptosis	Cardiovascular Disease Cancer
SB-590885 GMP is SB-590885 (HY-10966) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-590885 is a *BRAF/c-Raf* kinase inhibitor that selectively targets *B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits* the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BRAF inhibitors

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products